Table 1.
Patients who died within (cases) or survived (controls) 5 years of breast cancer diagnosis
| Patient Characteristic |
Cases/Dead
(n = 1212) |
Controls/Alive
(n = 8733) |
Total
(n = 9945) |
|||
|---|---|---|---|---|---|---|
| N or mean | % or SD | N or mean | % or SD | N or mean | % or SD | |
| Agea | ||||||
| <40 | 121 | 10% | 787 | 9% | 908 | 9% |
| 40–49 | 221 | 18% | 2403 | 28% | 2,624 | 26% |
| 50–59 | 251 | 21% | 2490 | 29% | 2,741 | 28% |
| 60–69 | 219 | 18% | 1794 | 21% | 2,013 | 20% |
| ≥70 | 400 | 33% | 1259 | 14% | 1,659 | 17% |
| Year of diagnosis | ||||||
| 2000–2003 | 334 | 28% | 2988 | 34% | 3,322 | 33% |
| 2004–2006 | 366 | 30% | 3222 | 37% | 3,588 | 36% |
| 2007–2009 | 402 | 33% | 2523 | 29% | 2,925 | 29% |
| 2010–2011 | 110 | 9% | 0 | 0% | 110 | 1% |
| Race | ||||||
| White/unknown | 997 | 82% | 7109 | 81% | 8,106 | 82% |
| Black | 62 | 5% | 192 | 2% | 254 | 3% |
| Asian/Pacific islander | 152 | 13% | 1423 | 16% | 1,575 | 16% |
| Native American | <10 | 0.1% | <10 | 0.1% | <10 | 0.1% |
| Marrieda | 661 | 55% | 5813 | 67% | 6,474 | 65% |
| Socioeconomic statusa | ||||||
| Lowest 20% | 74 | 6% | 266 | 3% | 340 | 3% |
| 21st–40th percentile | 142 | 12% | 607 | 7% | 749 | 8% |
| 41st–60th percentile | 174 | 14% | 975 | 11% | 1,149 | 12% |
| 61st–80th percentile | 245 | 20% | 1739 | 20% | 1,984 | 20% |
| Top 20% | 577 | 48% | 5146 | 59% | 5,723 | 58% |
| Hormone receptor subtype | ||||||
| ER+ only | 98 | 8% | 612 | 7% | 710 | 7% |
| ER+/PR+ and HER2+ | 115 | 9% | 819 | 9% | 934 | 9% |
| HER2+ only | 101 | 8% | 362 | 4% | 463 | 5% |
| PR+ only | 420 | 35% | 4406 | 50% | 4,826 | 49% |
| TNBC | 264 | 22% | 589 | 7% | 853 | 9% |
| Unknown | 214 | 18% | 1945 | 22% | 2,159 | 22% |
| Stagea | ||||||
| Stage 0 | 49 | 4% | 1736 | 20% | 1,785 | 18% |
| Stage I | 219 | 18% | 3260 | 37% | 3,479 | 35% |
| Stage II | 351 | 29% | 2576 | 29% | 2,927 | 29% |
| Stage III | 262 | 22% | 548 | 6% | 810 | 8% |
| Stage IV | 252 | 21% | 89 | 1% | 341 | 3% |
| Unknown | 79 | 7% | 524 | 6% | 603 | 6% |
| Gradea | ||||||
| Grade I | 101 | 8% | 1714 | 20% | 1815 | 18% |
| Grade II | 321 | 26% | 3451 | 40% | 3772 | 38% |
| Grade III | 527 | 43% | 2031 | 23% | 2558 | 26% |
| Grade IV | 43 | 4% | 501 | 6% | 544 | 5% |
| Unknown | 220 | 18% | 1036 | 12% | 1256 | 13% |
| Ductal tumora | 1,033 | 85% | 7459 | 85% | 8492 | 85% |
| Behavior of tumora | ||||||
| In situ | 62 | 5% | 2058 | 24% | 2120 | 21% |
| Malignant | 1150 | 95% | 6675 | 76% | 7825 | 79% |
| Bilaterala | 1164 | 96% | 8586 | 98% | 9750 | 98% |
| Lymph vascular invasiona | 35 | 3% | <10 | 0.1% | 41 | 0.4% |
| Comorbiditiesa | ||||||
| Myocardial infarction | <10 | 0.7% | 17 | 0.2% | 26 | 0.3% |
| Congestive heart failure | 15 | 1.2% | 11 | 0.1% | 26 | 0.3% |
| Peripheral vascular disease | 26 | 2% | 28 | 0.3% | 54 | 0.5% |
| Cerebrovascular disease | 34 | 3% | 66 | 0.8% | 100 | 1% |
| Dementia | <10 | 0.1% | <10 | 0.01% | <10 | 0.02% |
| Chronic obstructive pulmonary disease | 74 | 6% | 215 | 2% | 289 | 3% |
| Rheumatic disorders | <10 | 0.6% | 15 | 0.2% | 22 | 0.2% |
| Peptic ulcer disease | <10 | 0.0% | <10 | 0.01% | <10 | 0.01% |
| Liver, mild | <10 | 0.7% | <10 | 0.08% | 16 | 0.2% |
| Liver, severe | <10 | 0.5% | <10 | 0.02% | <10 | 0.08% |
| Diabetes (uncomplicated) | 25 | 2% | 44 | 0.5% | 69 | 0.7% |
| Diabetes (complicated) | <10 | 0.7% | <10 | 0.09% | 17 | 0.2% |
| Plegia | <10 | 0.0% | <10 | 0.03% | <10 | 0.03% |
| Renal disease | 17 | 1.4% | <10 | 0.1% | 26 | 0.3% |
| Malignancy | 286 | 24% | 1584 | 18% | 1870 | 19% |
| Metastasis | 61 | 5% | 57 | 1% | 118 | 1% |
| HIV | <10 | 0.4% | 10 | 0.1% | 15 | 0.2% |
| Charlson Comorbidity Scorea | 2.4 | 2.6 | 1.1 | 1.4 | 1.2 | 1.7 |
aAt: time of diagnosis; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer.